Sharps Technology's CEO Highlights Hungary Manufacturing Facility Expansion Plans To Increase SecureGard And SoloGard Product Supply And Revenue
Sharps Technology's CEO Highlights Hungary Manufacturing Facility Expansion Plans To Increase SecureGard And SoloGard Product Supply And Revenue
Sharps Technology的首席執行官強調了匈牙利製造業-半導體設施擴展計劃，以增加SecureGard和SoloGard產品的供應和營業收入。
-
Shareholder letter includes details about the $50+ million sales agreement with a US-based pharma company, plans for Hungary SoloGard manufacturing expansion, and expected delivery schedule
-
Initial production and commercial deliveries to begin in Q1 2025
-
Sales team has signed an agreement to sell and deliver current SecureGard 1mL and 3mL inventory, with shipments and revenue that began in early December
- 股東信函包含關於與一家美國藥品公司達成5000萬美元以上銷售協議的詳細信息、匈牙利SoloGard製造擴展計劃以及預期交付時間表。
- 初始生產和商業交付將在2025年第一季度開始。
- 銷售團隊已簽署協議，賣出並交付當前的SecureGard 1mL和3mL庫存，運送和營業收入於12月初開始。
NEW YORK, Dec. 05, 2024 (GLOBE NEWSWIRE) -- Sharps Technology, Inc., (NASDAQ: "STSS" and "STSSW"), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class syringe products, issues a shareholder letter from Robert Hayes, the Company's Chief Executive Officer.
紐約，2024年12月5日（環球新聞）-- Sharps Technology, Inc.（納斯達克: "STSS" 和 "STSSW"），是一家創新的器械和藥品包裝公司，提供專利、市場領先的注射器產品，發佈了公司首席執行官羅伯特·海斯的股東信函。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
資訊熱榜
更新時間